% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • underdogs14 underdogs14 Mar 29, 2014 2:14 PM Flag

    The way I see it..,


    INSM hit a high of $22.29 on 01/16/14. Since that time, Insmed reveals that the Arakayce (one year) extension study regarding Cystic Fibrosis patients indicates that subjects continue to demonstrate tangible improvement (even benefiting on the off 30 day cycle) with novel convenience from drug delivery.., when every other drug reflects worsening deterioration and a burdensome routine.

    We then get a 25% 'cure' rate from the {unmet medical need} three month NTM patient trial with Doctors applauding strengthening 'cure' rate percentages are resulting through the extension study and our stock is now sitting at $17.13.

    Can anyone argue that this will not become a LEGACY stock if not bought out sooner than later?

    This topic is deleted.
18.37-0.84(-4.37%)Oct 6 4:00 PMEDT